Our Pipelines 

AlphaMol Science are advancing several "first-in-class" drug discovery projects. The pipelines include super antibiotics, less side effect painkiller, cancer, diabetes and others. With the advantages of computational methods and innovative biotechnology in AlphaMol, we progress each pipeline in an ultimately efficient way.   

Super antibiotics

Antibiotics are medicines used to prevent and treat bacterial infections. Antibiotic resistance occurs when bacteria change in response to the use of these medicines. According to the report of WHO (World Health Organization) that antibiotic resistance is one of the biggest threats to global health, food security, and development today. Antibiotic resistance can affect anyone, of any age, in any country. If no action is taken - warns the UN Interagency Coordination Group on Antimicrobial Resistance who released the report – drug-resistant diseases could cause 10 million deaths each year by 2050 and damage to the economy as catastrophic as the 2008-2009 global financial crisis. By 2030, antimicrobial resistance could force up to 24 million people into extreme poverty. 

Within less than one year, AlphaMol has discovered new super antibiotic candidates based on poly-pharmacology mechanism. Our pre-clinical candidate (PCC ) can not only prevent the activities of several key enzymes inside bacteria, but can also influence the membrane properties of them.  It finally leads to a MIC in the range of 0.01 μg/ml to against multi-resistant and panresistant bacteria such as E. coli, baumannii, MRSA as well as E. faecium. The new drug candidate also demonstrated much better drug tolerance than both vancomycin and moxifloxacin via 3 weeks high stress experiment. A series of animal experiments also confirmed the safety of our PCC. 


Deaths from prescription painkillers have reached epidemic levels in the past decade. In 2019, nearly 50,000 people in the United States died from opioid-involved overdoses. The misuse of and addiction to opioids-including prescription pain relievers, heroin, and synthetic opioids such as fentanyl—is a serious national crisis that affects public health as well as social and economic welfare. 

How to prevent side effects of painkiller and keep the painkiller effect has become an urgent problem in modern drug discovery. The team of AlphaMol has worked on the molecular mechanism of related GPCR drug targets for more than 10 years. A potential new mechanism has been illuminated recently which now applied to less side effect painkiller pipeline. 


Cancer is one of the biggest threats to the human health. AlphaMol discovered new immu-oncology small molecules to treat different cancers. We expect those active compounds can be used as a treatment for general cancer diseases. 


Diabetes has become more and more popular in both developed and developing countries. According to the investigation of CDCs (Centers for disease Control) in both United States and China, about 10% populations of both countries which equal to  about 180 million people are suffering from diabetes at different levels. 

Insulin and other peptide analogs are effective drugs for diabetes treatment. Patience needs to inject those peptide drugs everyday which brings  a lot suffers for them as well. The team of AlphaMol discovered a new family A orphan GPCR  which could be a promising target to develop oral small molecules for diabetes.  The lead compound for this target has been invented with less than 4 months.